Intercept Pharmaceuticals Inc. (ICPT) Given Average Rating of “Hold” by Brokerages
Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) has received a consensus recommendation of “Hold” from the twenty research firms that are currently covering the stock. Five equities research analysts have rated the stock with a sell recommendation, four have issued a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $176.46.
ICPT has been the subject of several recent analyst reports. Wedbush reiterated an “outperform” rating and issued a $239.00 price objective on shares of Intercept Pharmaceuticals in a report on Friday, September 16th. Zacks Investment Research cut shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Wednesday, November 2nd. Wells Fargo & Co. reiterated a “buy” rating on shares of Intercept Pharmaceuticals in a report on Wednesday, September 28th. Leerink Swann reissued a “positive” rating and set a $159.00 target price on shares of Intercept Pharmaceuticals in a research note on Friday, October 14th. Finally, Oppenheimer Holdings Inc. reissued an “outperform” rating and set a $200.00 target price (down from $250.00) on shares of Intercept Pharmaceuticals in a research note on Monday, October 24th.
In other news, insider Lisa Bright sold 246 shares of the stock in a transaction on Thursday, August 25th. The shares were sold at an average price of $159.00, for a total transaction of $39,114.00. Following the transaction, the insider now owns 18,460 shares in the company, valued at approximately $2,935,140. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Mark Pruzanski sold 35,000 shares of the stock in a transaction on Tuesday, September 20th. The stock was sold at an average price of $165.00, for a total transaction of $5,775,000.00. Following the transaction, the chief executive officer now owns 579,314 shares in the company, valued at approximately $95,586,810. The disclosure for this sale can be found here. Insiders own 9.20% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. CENTRAL TRUST Co acquired a new position in shares of Intercept Pharmaceuticals during the second quarter valued at approximately $107,000. KBC Group NV raised its position in shares of Intercept Pharmaceuticals by 660.2% in the third quarter. KBC Group NV now owns 897 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 779 shares during the period. Legal & General Group Plc raised its position in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock valued at $171,000 after buying an additional 52 shares during the period. Metropolitan Life Insurance Co. NY raised its position in shares of Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock valued at $176,000 after buying an additional 38 shares during the period. Finally, Pacer Advisors Inc. acquired a new position in shares of Intercept Pharmaceuticals during the second quarter valued at approximately $180,000. Institutional investors own 81.82% of the company’s stock.
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 111.86 on Monday. The stock’s market capitalization is $2.77 billion. Intercept Pharmaceuticals has a 1-year low of $89.76 and a 1-year high of $186.87. The firm has a 50-day moving average of $137.24 and a 200 day moving average of $147.77.
Intercept Pharmaceuticals (NASDAQ:ICPT) last posted its quarterly earnings data on Thursday, November 3rd. The biopharmaceutical company reported ($3.59) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.82) by $0.23. The business earned $4.70 million during the quarter, compared to analysts’ expectations of $4.77 million. Intercept Pharmaceuticals had a negative net margin of 3,287.95% and a negative return on equity of 66.97%. The business’s revenue was up 1051.1% on a year-over-year basis. During the same period last year, the firm posted ($2.10) earnings per share. On average, equities analysts anticipate that Intercept Pharmaceuticals will post ($15.77) earnings per share for the current fiscal year.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Stock Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.